121 related articles for article (PubMed ID: 16211877)
1. Clinical trial designs for therapeutic cancer vaccines.
Simon R
Cancer Treat Res; 2005; 123():339-50. PubMed ID: 16211877
[TBL] [Abstract][Full Text] [Related]
2. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
Simon RM; Steinberg SM; Hamilton M; Hildesheim A; Khleif S; Kwak LW; Mackall CL; Schlom J; Topalian SL; Berzofsky JA
J Clin Oncol; 2001 Mar; 19(6):1848-54. PubMed ID: 11251017
[TBL] [Abstract][Full Text] [Related]
4. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
5. Cancer vaccine THERATOPE- Biomira.
Adis International Ltd
Drugs R D; 2003; 4(4):236-40. PubMed ID: 12848588
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian adaptive phase I-II trial design for optimizing the schedule of therapeutic cancer vaccines.
Cunanan KM; Koopmeiners JS
Stat Med; 2017 Jan; 36(1):43-53. PubMed ID: 27545299
[TBL] [Abstract][Full Text] [Related]
7. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II designs in cancer clinical trials: current status and future directions.
Lee JJ; Feng L
J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
[TBL] [Abstract][Full Text] [Related]
9. A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges.
Chen YH; Gesser R; Luxembourg A
Clin Trials; 2015 Feb; 12(1):84-90. PubMed ID: 25278227
[TBL] [Abstract][Full Text] [Related]
10. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
[TBL] [Abstract][Full Text] [Related]
11. Design of clinical trials for therapeutic cancer vaccines development.
Mackiewicz J; Mackiewicz A
Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
[TBL] [Abstract][Full Text] [Related]
12. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
[TBL] [Abstract][Full Text] [Related]
13. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
14. Design of Phase II cancer trials evaluating survival probabilities.
Case LD; Morgan TM
BMC Med Res Methodol; 2003 Apr; 3():6. PubMed ID: 12697051
[TBL] [Abstract][Full Text] [Related]
15. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
16. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
Messer K; Natarajan L; Ball ED; Lane TA
Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
[TBL] [Abstract][Full Text] [Related]
17. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Karrison TG; Maitland ML; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
[TBL] [Abstract][Full Text] [Related]
18. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
André FE; Foulkes MA
Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic cancer vaccines: From initial findings to prospects.
Song Q; Zhang CD; Wu XH
Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
[TBL] [Abstract][Full Text] [Related]
20. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives.
Seymour L
Curr Pharm Des; 2002; 8(25):2279-84. PubMed ID: 12369856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
